Latest ARAY news and sentiment

What Accuray’s (ARAY) $8 Million RaySearch Deal Means for Its Adaptive Therapy Push

Accuray Inc. (ARAY) has entered an $8 million agreement with RaySearch Laboratories to extend their alliance, aiming to accelerate the adoption of online adaptive radiation therapy. This collaboration integrates Accuray's imaging and radiation therapy platforms with RaySearch's planning solutions, focusing initially on the Radixact system. While the deal supports Accuray's transformation plan and growth strategy, potential risks include slow adoption by healthcare providers and dependency on RaySearch's execution.

Accuray Inc. (NASDAQ: ARAY) Announces Resale of 6.83M Shares Linked to Warrants Priced at $1.50, $1.25, and $0.01

Accuray Inc. (NASDAQ: ARAY) has announced the resale of up to 6.83 million common shares by selling stockholders, tied to warrants exercisable at $1.50, $1.25, and $0.01 per share. The company will not receive proceeds from these resales, but any cash warrant exercises would be used for general corporate purposes. This transaction involves various warrant types, including Super Premium, Premium, and Penny Warrants, issued as part of a financing agreement from June 2025.

Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities

MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated) The collaboration combines Accuray's advanced photon-based radiation therapy platforms and imaging capabilities with RaySearch's treatmen

Accuray Inc (NASDAQ: ARAY) Discloses 18.7% Beneficial Ownership by TCW Including Warrants

Accuray Inc. (NASDAQ: ARAY) has disclosed that The TCW Group holds an 18.7% beneficial ownership, which includes 27,527,916 common shares convertible from warrants. This ownership stems from an amended financing agreement that provides a covenant holiday until December 31, 2027, grants TCW preferred director rights, and includes a $15 million fee if stockholder approval is not secured.

Accuray (ARAY) Q4 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Financial Planning and Analysis - Stephen Monroe President and Chief Executive Officer - Stephen R. LaNeve Chief Financial Officer - Ali Pervaiz Full Conference Call Transcript Operator: Good day, and welcome to the Accuray Fourth Quarter Fiscal 26 Financial Results Conference Call. All participants will be in a listen-only mode. [Inaudible] by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may p

Accuray (ARAY) sends definitive proxy to shareholders

Accuray Inc. has submitted a definitive proxy statement to the SEC, detailing proposals for its 2026 Special Meeting of Stockholders on October 6, 2026. The company is seeking stockholder approval for a financing transaction involving the issuance of Series A Convertible Preferred Stock and warrants, a significant increase in authorized common stock, and a reverse stock split. These actions are crucial for strengthening Accuray's financial position, addressing liquidity concerns, and maintaining its listing on The Nasdaq Capital Market.

Penny-priced Accuray (NASDAQ: ARAY) warrants set up lender share resales

Accuray Incorporated has filed an amended Form S-3 registration statement to allow certain existing lenders to resell up to 6,834,308 shares of common stock. These shares are tied to previously issued Super Premium, Premium, and Penny Warrants, which were granted in connection with a senior secured Financing Agreement including an $18.25 million delayed draw term loan. Accuray will not receive proceeds from the resales but would benefit if warrant holders exercise them for cash; the company's stock currently trades at $0.29 per share, while warrant exercise prices range from $0.01 to $1.50.

Accuray Incorporated Q4 Operating Expenses US

This article provides an in-depth financial analysis of Accuray Incorporated's Q4 operating expenses in the US, highlighting key figures and trends. It breaks down the components of their expenditures, offering insights into the company's financial health and operational efficiency during the quarter.

Accuray Incorporated 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:ARAY) 2026-08-20

This article announces that Accuray Incorporated has published its Q4 2026 earnings call presentation. The presentation was released in conjunction with their earnings call on August 20, 2026. Seeking Alpha's transcripts team prepared this content.

Accuray Inc (ARAY) (Q4 2026) Earnings Call Highlights: Strategic Transformation and Financial ...

Accuray expects $15M of incremental annualized cost and margin improvement in FY27 while withholding formal revenue and adjusted EBITDA guidance

Earnings Call Insights: Accuray (ARAY) Q4 2026 MANAGEMENT VIEW * “Fiscal 2026 was an important year for Accuray. Last October, we began a comprehensive effort to evaluate every aspect of our business… streamline our organization… reduced our cost structure… worked towards expanding partnerships and taken significant steps to improve our financial position.” (President, CEO & Director Stephen LaNeve) * “Last month, we announced a comprehensive transaction with TCW, Asset Management Company LLC that fundamentally strengthens our financial position and enhances our ability to execute our strategy

Aug 19 (Reuters) - Accuray Incorporated Q4 Ne

This article is a Reuters news brief from August 19, reporting on Accuray Incorporated's Q4 results. The content is incomplete, only providing the headline and indicating that it's a financial news update.

Earnings call transcript: Accuray posts mixed Q4 2026 results as revenue slips

Accuray Inc. reported mixed financial results for Q4 fiscal year 2026, beating EPS estimates but missing revenue forecasts. The company's revenue declined significantly year-over-year, primarily due to a sharp drop in product sales, especially from China, though service revenue saw growth. Accuray did not provide formal guidance for fiscal year 2027 due to geopolitical and tariff uncertainties but outlined expectations for continued service revenue growth and improved margins.